Geranylgeraniol (GGOH) as a Mevalonate Pathway Activator in the Rescue of Bone Cells Treated with Zoledronic Acid: An In Vitro Study
Bisphosphonates (BPs) are the keystone to treat bone disorders. Despite the great benefits of BPs, medication-related osteonecrosis of the jaw (MRONJ) arouse as a potential side effect. Nitrogen-containing BPs (N-BPs) as zoledronate (ZA) act by the inhibition of specific enzymes of the mevalonate pa...
Saved in:
Main Authors: | Riham M. Fliefel (Author), Saleh A. Entekhabi (Author), Michael Ehrenfeld (Author), Sven Otto (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In vitro Effect of Geranylgeraniol (GGOH) on Bisphosphonate-Induced Cytotoxicity of Oral Mucosa Cells
by: Krit Rattanawonsakul, et al.
Published: (2022) -
Geranylgeraniol (GGOH), incorporated into a bone cement pellet promotes osteoclast function and healing in a model of medication-related osteonecrosis of the jaw
by: George Feldman, et al.
Published: (2024) -
Zoledronic Acid Targeting of the Mevalonate Pathway Causes Reduced Cell Recruitment and Attenuates Pulmonary Fibrosis
by: Lloyd Tanner, et al.
Published: (2022) -
Zoledronic acid in the management of metastatic bone disease
by: Thomas J Polascik, et al.
Published: (2008) -
The Role of Geranylgeraniol in Managing Bisphosphonate-Related Osteonecrosis of the Jaw
by: Kok-Yong Chin, et al.
Published: (2022)